Cargando…
EP3 receptor antagonist L798,106 reduces proliferation and migration of SK-BR-3 breast cancer cells
Purpose: COX-2 overexpression and elevated levels of prostaglandin E2 (PGE2) play an important role in breast cancer carcinogenesis. Recently, expression of the PGE2 receptor EP3 has been shown to be a positive prognostic factor in breast cancer. This study analyzes the functional aspects of targeti...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6680222/ https://www.ncbi.nlm.nih.gov/pubmed/31534346 http://dx.doi.org/10.2147/OTT.S204919 |
_version_ | 1783441456609886208 |
---|---|
author | Hester, Anna Salzmann, Barbara Rahmeh, Martina Kolben, Thomas Czogalla, Bastian Ditsch, Nina Mahner, Sven Jeschke, Udo Kolben, Theresa Maria |
author_facet | Hester, Anna Salzmann, Barbara Rahmeh, Martina Kolben, Thomas Czogalla, Bastian Ditsch, Nina Mahner, Sven Jeschke, Udo Kolben, Theresa Maria |
author_sort | Hester, Anna |
collection | PubMed |
description | Purpose: COX-2 overexpression and elevated levels of prostaglandin E2 (PGE2) play an important role in breast cancer carcinogenesis. Recently, expression of the PGE2 receptor EP3 has been shown to be a positive prognostic factor in breast cancer. This study analyzes the functional aspects of targeting EP3 in breast cancer cell lines. Material and methods: EP3 and EP1 expressions were determined in five breast cancer cell lines on the mRNA- and the protein-level. The selected cell lines were subsequently stimulated for 24–72 hrs with 10–1,000 nM of PGE2, the EP1/EP3 agonist sulprostone and the EP3 antagonist L798,106. Cell proliferation was determined via BrdU-assay, migration via scratch assay, EP3, Gi-protein and p-ERK1/2 expressions via Western blot and cAMP concentrations via ELISA. The Mann–Whitney-U-test was used to test for statistical significance. Results: The cell lines T-47D (EP3 expression 77.7%) and SK-BR-3 (EP3 expression 48.7%) were chosen. EP3 antagonism reduced its expression on SK-BR-3 significantly, while no effect was observed on T-47D. The proliferation and migration of SK-BR-3 cells were significantly reduced due to treatment with the EP1/3 agonist, the EP3 antagonist or a combination of both. Neither agonism nor antagonism influenced cell proliferation or migration in T-47D. In SK-BR-3, EP3 antagonism showed a significant decrease in Gi-protein levels, an increase in cAMP levels, and no significant change in p-ERK1/2 expression. Conclusion: Antagonism of the EP3 receptor results in a reduced proliferation and migration of SK-BR-3 breast cancer cells, potentially mediated via a Gi-protein-cAMP pathway. The results suggest that EP3 plays a role in tumorigenesis. This is in accordance with the cell culture data of other gynecological tumors, but it is conflicting in so far, as positive EP3 expression is clinically a positive prognostic marker in breast cancer. Therefore, other factors may be important in explaining this contradiction. |
format | Online Article Text |
id | pubmed-6680222 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-66802222019-09-18 EP3 receptor antagonist L798,106 reduces proliferation and migration of SK-BR-3 breast cancer cells Hester, Anna Salzmann, Barbara Rahmeh, Martina Kolben, Thomas Czogalla, Bastian Ditsch, Nina Mahner, Sven Jeschke, Udo Kolben, Theresa Maria Onco Targets Ther Original Research Purpose: COX-2 overexpression and elevated levels of prostaglandin E2 (PGE2) play an important role in breast cancer carcinogenesis. Recently, expression of the PGE2 receptor EP3 has been shown to be a positive prognostic factor in breast cancer. This study analyzes the functional aspects of targeting EP3 in breast cancer cell lines. Material and methods: EP3 and EP1 expressions were determined in five breast cancer cell lines on the mRNA- and the protein-level. The selected cell lines were subsequently stimulated for 24–72 hrs with 10–1,000 nM of PGE2, the EP1/EP3 agonist sulprostone and the EP3 antagonist L798,106. Cell proliferation was determined via BrdU-assay, migration via scratch assay, EP3, Gi-protein and p-ERK1/2 expressions via Western blot and cAMP concentrations via ELISA. The Mann–Whitney-U-test was used to test for statistical significance. Results: The cell lines T-47D (EP3 expression 77.7%) and SK-BR-3 (EP3 expression 48.7%) were chosen. EP3 antagonism reduced its expression on SK-BR-3 significantly, while no effect was observed on T-47D. The proliferation and migration of SK-BR-3 cells were significantly reduced due to treatment with the EP1/3 agonist, the EP3 antagonist or a combination of both. Neither agonism nor antagonism influenced cell proliferation or migration in T-47D. In SK-BR-3, EP3 antagonism showed a significant decrease in Gi-protein levels, an increase in cAMP levels, and no significant change in p-ERK1/2 expression. Conclusion: Antagonism of the EP3 receptor results in a reduced proliferation and migration of SK-BR-3 breast cancer cells, potentially mediated via a Gi-protein-cAMP pathway. The results suggest that EP3 plays a role in tumorigenesis. This is in accordance with the cell culture data of other gynecological tumors, but it is conflicting in so far, as positive EP3 expression is clinically a positive prognostic marker in breast cancer. Therefore, other factors may be important in explaining this contradiction. Dove 2019-07-29 /pmc/articles/PMC6680222/ /pubmed/31534346 http://dx.doi.org/10.2147/OTT.S204919 Text en © 2019 Hester et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Hester, Anna Salzmann, Barbara Rahmeh, Martina Kolben, Thomas Czogalla, Bastian Ditsch, Nina Mahner, Sven Jeschke, Udo Kolben, Theresa Maria EP3 receptor antagonist L798,106 reduces proliferation and migration of SK-BR-3 breast cancer cells |
title | EP3 receptor antagonist L798,106 reduces proliferation and migration of SK-BR-3 breast cancer cells |
title_full | EP3 receptor antagonist L798,106 reduces proliferation and migration of SK-BR-3 breast cancer cells |
title_fullStr | EP3 receptor antagonist L798,106 reduces proliferation and migration of SK-BR-3 breast cancer cells |
title_full_unstemmed | EP3 receptor antagonist L798,106 reduces proliferation and migration of SK-BR-3 breast cancer cells |
title_short | EP3 receptor antagonist L798,106 reduces proliferation and migration of SK-BR-3 breast cancer cells |
title_sort | ep3 receptor antagonist l798,106 reduces proliferation and migration of sk-br-3 breast cancer cells |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6680222/ https://www.ncbi.nlm.nih.gov/pubmed/31534346 http://dx.doi.org/10.2147/OTT.S204919 |
work_keys_str_mv | AT hesteranna ep3receptorantagonistl798106reducesproliferationandmigrationofskbr3breastcancercells AT salzmannbarbara ep3receptorantagonistl798106reducesproliferationandmigrationofskbr3breastcancercells AT rahmehmartina ep3receptorantagonistl798106reducesproliferationandmigrationofskbr3breastcancercells AT kolbenthomas ep3receptorantagonistl798106reducesproliferationandmigrationofskbr3breastcancercells AT czogallabastian ep3receptorantagonistl798106reducesproliferationandmigrationofskbr3breastcancercells AT ditschnina ep3receptorantagonistl798106reducesproliferationandmigrationofskbr3breastcancercells AT mahnersven ep3receptorantagonistl798106reducesproliferationandmigrationofskbr3breastcancercells AT jeschkeudo ep3receptorantagonistl798106reducesproliferationandmigrationofskbr3breastcancercells AT kolbentheresamaria ep3receptorantagonistl798106reducesproliferationandmigrationofskbr3breastcancercells |